


a 2021 0058

The invention relates to the chemistry of natural compounds and medicinal chemistry, in particular to the use of an *ent*-kaurenoic acid derivative containing an azide functional group as a chemotherapeutic agent for the treatment of oncological diseases.

According to the invention, claimed is the use of methyl *ent*-16-azido-17-carboxyethoxyme-thylkauranoate with the formula



as selective cytotoxic compound, for which selective inhibition of Z-138 tumor cell line (non-Hodgkin lymphoma) proliferation has been demonstrated at an  $IC_{50}$  value equal to 0.5  $\mu\text{g/mL}$ .

Claims: 1

Fig.: 3